These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 33813727)

  • 1. Prasugrel switching from clopidogrel after percutaneous coronary intervention for acute coronary syndrome in Taiwanese patients: an analysis of safety and efficacy.
    Liu PY; Su CH; Kuo FY; Lee WL; Wang YC; Lin WS; Chu PH; Lu TM; Lo PH; Lee CH; Lan WR; Huang CL; Tsukiyama S; Yang WC; Cheng LC; Rafael V; Nikolajsen C; Yin WH
    Cardiovasc Interv Ther; 2022 Apr; 37(2):269-278. PubMed ID: 33813727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of CYP2C19 status on platelet reactivity in Taiwanese acute coronary syndrome patients switching to prasugrel from clopidogrel: Switch Study.
    Kuo FY; Lee CH; Lan WR; Su CH; Lee WL; Wang YC; Lin WS; Chu PH; Lu TM; Lo PH; Tsukiyama S; Yang WC; Cheng LC; Huang CL; Yin WH; Liu PY
    J Formos Med Assoc; 2022 Sep; 121(9):1786-1797. PubMed ID: 35115197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prasugrel effectively reduces the platelet reactivity units in patients with genetically metabolic dysfunction of cytochrome P450 2C19 who are treated with long-term dual antiplatelet therapy after undergoing drug-eluting stent implantation.
    Shimamatsu J; Sasaki KI; Katsuki Y; Kawasaki T; Murasato Y; Ajisaka H; Yokoi H; Tashiro H; Harada A; Hirakawa Y; Ishizaki Y; Ishimatsu T; Kagiyama K; Fukumoto Y; Kakuma T; Ueno T
    Heart Vessels; 2020 Mar; 35(3):312-322. PubMed ID: 31549178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in P2Y12 reaction units after switching treatments from prasugrel to clopidogrel in Japanese patients with acute coronary syndrome followed by elective coronary stenting.
    Ueno T; Koiwaya H; Sasaki KI; Katsuki Y; Katsuda Y; Murasato Y; Shimamatsu J; Umeji K; Otsuka Y; Kawasaki T; Shibata Y; Fukumoto Y
    Cardiovasc Interv Ther; 2017 Oct; 32(4):341-350. PubMed ID: 27488859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.
    Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S;
    Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry.
    Clemmensen P; Grieco N; Ince H; Danchin N; Goedicke J; Ramos Y; Schmitt J; Goldstein P;
    Eur Heart J Acute Cardiovasc Care; 2015 Jun; 4(3):220-9. PubMed ID: 25182465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
    Ogawa H; Isshiki T; Kimura T; Yokoi H; Nanto S; Takayama M; Kitagawa K; Nishikawa M; Miyazaki S; Ikeda Y; Nakamura M; Tanaka Y; Saito S
    J Cardiol; 2016 Jul; 68(1):29-36. PubMed ID: 26521100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De-escalation of dual antiplatelet therapy for patients with acute coronary syndrome after percutaneous coronary intervention: a systematic review and network meta-analysis.
    De Filippo O; Piroli F; Bruno F; Bocchino PP; Saglietto A; Franchin L; Angelini F; Gallone G; Rizzello G; Ahmad M; Gasparini M; Chatterjee S; De Ferrari GM; D'Ascenzo F
    BMJ Evid Based Med; 2024 May; 29(3):171-186. PubMed ID: 38242567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment.
    Shoji S; Sawano M; Sandhu AT; Heidenreich PA; Shiraishi Y; Ikemura N; Ueno K; Suzuki M; Numasawa Y; Fukuda K; Kohsaka S
    JAMA Netw Open; 2020 Apr; 3(4):e202004. PubMed ID: 32239221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal cutoff value of P2Y12 reaction units to prevent major adverse cardiovascular events in the acute periprocedural period: post-hoc analysis of the randomized PRASFIT-ACS study.
    Nakamura M; Isshiki T; Kimura T; Ogawa H; Yokoi H; Nanto S; Takayama M; Kitagawa K; Ikeda Y; Saito S
    Int J Cardiol; 2015 Mar; 182():541-8. PubMed ID: 25679803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of reduced-dose prasugrel vs. standard-dose clopidogrel on in-hospital outcomes of percutaneous coronary intervention in 62 737 patients with acute coronary syndromes: a nationwide registry study in Japan.
    Akita K; Inohara T; Yamaji K; Kohsaka S; Numasawa Y; Ishii H; Amano T; Kadota K; Nakamura M; Maekawa Y
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):231-238. PubMed ID: 31593213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet inhibition after loading dose of prasugrel in patients with ST-elevation and non-ST-elevation acute coronary syndrome.
    Wakabayashi S; Kitahara H; Nishi T; Sugimoto K; Nakayama T; Fujimoto Y; Ariyoshi N; Kobayashi Y
    Cardiovasc Interv Ther; 2018 Jul; 33(3):239-246. PubMed ID: 28608310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.
    Saucedo JF; Angiolillo DJ; DeRaad R; Frelinger AL; Gurbel PA; Costigan TM; Jakubowski JA; Ojeh CK; Duvvuru S; Effron MB;
    Thromb Haemost; 2013 Feb; 109(2):347-55. PubMed ID: 23223867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the Clinical Treatment Dynamics of Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention in the US.
    Wang Y; Cavallari LH; Brown JD; Thomas CD; Winterstein AG
    JAMA Netw Open; 2023 Apr; 6(4):e238585. PubMed ID: 37067798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of low-dose prasugrel on platelet reactivity and cardiac dysfunction in acute coronary syndrome patients requiring primary drug-eluting stent implantation: A randomized comparative study.
    Kitano D; Takayama T; Fukamachi D; Migita S; Morikawa T; Tamaki T; Kojima K; Mineki T; Murata N; Akutsu N; Sudo M; Hiro T; Hirayama A; Okumura Y
    Catheter Cardiovasc Interv; 2020 Jan; 95(1):E8-E16. PubMed ID: 30983087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel: a pre-specified exploratory analysis from the TROPICAL-ACS trial.
    Aradi D; Gross L; Trenk D; Geisler T; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Ruzsa Z; Ungi I; Rizas KD; May AE; Mügge A; Zeiher AM; Holdt L; Huber K; Neumann FJ; Koltowski L; Huczek Z; Hadamitzky M; Massberg S; Sibbing D
    Eur Heart J; 2019 Jun; 40(24):1942-1951. PubMed ID: 31226213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial.
    Diodati JG; Saucedo JF; Cardillo TE; Jakubowski JA; Henneges C; Effron MB; Lipkin FR; Walker JR; Duvvuru S; Sundseth SS; Fisher HN; Angiolillo DJ
    Thromb Haemost; 2014 Aug; 112(2):311-22. PubMed ID: 24718367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Prasugrel Compared With Clopidogrel for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    Wang A; Lella LK; Brener SJ
    Am J Ther; 2016; 23(6):e1637-e1643. PubMed ID: 24942006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
    Aradi D; Tornyos A; Pintér T; Vorobcsuk A; Kónyi A; Faluközy J; Veress G; Magyari B; Horváth IG; Komócsi A
    J Am Coll Cardiol; 2014 Mar; 63(11):1061-70. PubMed ID: 24486281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Impact of novel P2Y12 receptor inhibitors on platelet reactivity in acute coronary syndrome patients undergoing percutaneous coronary intervention].
    Chong Tou TJ; Liu PM; Wang JF; Sio Cham ZC; O U YF; Lei Sio ZW; Lei Put PZ; Lei Sok SM; Zhou SX; Wu W
    Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Feb; 44(2):138-43. PubMed ID: 26926507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.